|
1
|
Pratley RE and Weyer C: The role of
impaired early insulin secretion in the pathogenesis of type II
diabetes mellitus. Diabetologia. 44(929)2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
American Diabetes Association. 15.
Diabetes care in the hospital: Standards of medical care in
diabetes-2020. Diabetes Care. 43 (Suppl 1):S193–S202.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Haak T: Initial combination with
linagliptin and metformin in newly diagnosed type 2 diabetes and
severe hyperglycemia. Adv Ther. 29:1005–1015. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
American Diabetes Association. 5.
Lifestyle management: Standards of medical care in diabetes-2019.
Diabetes Care. 42 (Suppl 1):S46–S60. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Garber AJ, Abrahamson MJ, Barzilay JI,
Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA,
Einhorn D, Fonseca VA, et al: Consensus statement by the American
association of clinical endocrinologists and American college of
endocrinology on the comprehensive type 2 diabetes management
algorithm-2017 executive summary. Endocr Pract. 23:207–238.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
American Diabetes Association Approaches
to glycemic treatment. Sec. 7. In standards of medical care in
diabetes-2016. Diabetes Care. 39 (Suppl 1):S52–S59. 2016.
|
|
7
|
American Diabetes Association. 9.
Pharmacologic approaches to glycemic treatment: Standards of
medical care in diabetes-2019. Diabetes Care. 42 (Suppl
1):S90–S102. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pastores SM: ACP journal club. Review:
Intensive insulin therapy does not reduce mortality but increases
severe hypoglycemia in hospitalized patients. Ann Intern Med.
155:JC1–JC12. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nyenwe E: Intensive insulin therapy in
hospitalised patients increases the risk of hypoglycaemia and has
no effect on mortality, infection risk or length of stay. Evid
Based Med. 17:8–9. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Aleali AM, Payami SP, Latifi SM,
Yazdanpanah L, Hesam S and Khajeddin N: Evaluation of psychological
resistance to insulin treatment in type II diabetic patients.
Diabetes Metab Syndr. 12:929–932. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sanchez-Rangel E and Inzucchi SE:
Metformin: Clinical use in type 2 diabetes. Diabetologia.
60:1586–1593. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zinman B, Aroda VR, Buse JB, Cariou B,
Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ and Araki E:
PIONEER 8 Investigators. Efficacy, safety, and tolerability of oral
semaglutide versus placebo added to insulin with or without
metformin in patients with type 2 diabetes: The PIONEER 8 trial.
Diabetes Care. 42:2262–2271. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Scott R, Morgan J, Zimmer Z, Lam RLH,
O'Neill EA, Kaufman KD, Engel SS and Raji A: A randomized clinical
trial of the efficacy and safety of sitagliptin compared with
dapagliflozin in patients with type 2 diabetes mellitus and mild
renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab.
20:2876–2884. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Thornberry NA and Gallwitz B: Mechanism of
action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract
Res Clin Endocrinol Metab. 23:479–486. 2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ahrén B, Landin-Olsson M, Jansson PA,
Svensson M, Holmes D and Schweizer A: Inhibition of dipeptidyl
peptidase-4 reduces glycemia, sustains insulin levels, and reduces
glucagon levels in type 2 diabetes. J Clin Endocrinol Metab.
89:2078–2084. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dicker D: DPP-4 inhibitors: Impact on
glycemic control and cardiovascular risk factors. Diabetes Care. 34
(Suppl 2):S276–S278. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
American Diabetes Association. Standards
of medical care in diabetes-2013. Diabetes Care. 36 (Suppl
1):S11–S66. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
Insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Burden RL and Faires JD: Numerical
analysis. J R Statist Soc. 71:48–50. 2005.
|
|
20
|
Li Q, Wang L, Xiao L, Wang Z, Wang F, Yu
X, Yan S and Wang Y: Effect of intensive insulin therapy on
first-phase insulin secretion in newly diagnosed type 2 diabetic
patients with a family history of the disease. Exp Ther Med.
9:612–618. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li G, Yang W and Jiang Y: The possibility
of (FINSxFPG)/(PG2h+PG1h-2FPG) being taken as an index of
pancreatic β cell insulin secretion in a population based study.
Chin J Intern Med. 13:191–196. 2000.
|
|
22
|
Kang X, Wang C, Chen D, Lv L, Liu G, Xiao
J, Yang Y, He L, Chen L, Li X, et al: Contributions of basal
glucose and postprandial glucose concentrations to hemoglobin A1c
in the newly diagnosed patients with type 2 diabetes-the
preliminary study. Diabetes Technol Ther. 17:445–448.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Weir GC, Marselli L, Marchetti P, Katsuta
H, Jung MH and Bonner-Weir S: Towards better understanding of the
contributions of overwork and glucotoxicity to the beta-cell
inadequacy of type 2 diabetes. Diabetes Obes Metab. 11 (Suppl
4):82–90. 2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Defronzo RA, Eldor R and Abdul-Ghani M:
Pathophysiologic approach to therapy in patients with newly
diagnosed type 2 diabetes. Diabetes Care. 36 (Suppl 2):S127–S138.
2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang
C, Liu G and Ran X: Effects of dipeptidyl peptidase-4 inhibitors on
beta-cell function and insulin resistance in type 2 diabetes:
Meta-analysis of randomized controlled trials. Sci Rep.
7(44865)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cnop M, Vidal J, Hull RL, Utzschneider KM,
Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY and Kahn SE:
Progressive loss of beta-cell function leads to worsening glucose
tolerance in first-degree relatives of subjects with type 2
diabetes. Diabetes Care. 30:677–382. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mu J, Petrov A, Eiermann GJ, Woods J, Zhou
YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, et al: Inhibition of
DPP-4 with sitagliptin improves glycemic control and restores islet
cell mass and function in a rodent model of type 2 diabetes. Eur J
Pharmacol. 623:148–154. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Heise T, Larbig M, Patel S, Seck T, Hehnke
U, Woerle HJ and Dugi K: The dipeptidyl peptidase-4 inhibitor
linagliptin lowers postprandial glucose and improves measures of
β-cell function in type 2 diabetes. Diabetes Obes Metab.
16:1036–1039. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Leibowitz G, Cahn A, Bhatt DL, Hirshberg
B, Mosenzon O, Wei C, Jermendy G, Sheu WH, Sendon JL, Im K, et al:
Impact of treatment with saxagliptin on glycaemic stability and
β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab.
17:487–494. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tarantino G, Citro V and Capone D:
Nonalcoholic fatty liver disease: A challenge from mechanisms to
therapy. J Clin Med. 9(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Iwasaki T, Yoneda M, Inamori M, Shirakawa
J, Higurashi T, Maeda S, Terauchi Y and Nakajima A: Sitagliptin as
a novel treatment agent for non-alcoholic fatty liver disease
patients with type 2 diabetes mellitus. Hepatogastroenterology.
58:2103–2105. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta
RA, Sung J, Westerbacka J, Bailey TS and Blonde L: Real-world
evidence concerning clinical and economic outcomes of switching to
insulin glargine 300 U/ml vs other basal insulins in patients with
type 2 diabetes using basal insulin. Diabetes Obes Metab.
20:1293–1297. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kelany ME, Hakami TM, Omar AH and Abdallah
MA: Combination of sitagliptin and insulin against type 2 diabetes
mellitus with neuropathy in rats: Neuroprotection and role of
oxidative and inflammation stress. Pharmacology. 98:242–250.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ramírez E, Picatoste B, González-Bris A,
Oteo M, Cruz F, Caro-Vadillo A, Egido J, Tuñón J, Morcillo MA and
Lorenzo Ó: Sitagliptin improved glucose assimilation in detriment
of fatty-acid utilization in experimental type-II diabetes: Role of
GLP-1 isoforms in Glut4 receptor trafficking. Cardiovasc Diabetol.
17(12)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
American Diabetes Association. 4.
Lifestyle management: Standards of medical care in diabetes-2018.
Diabetes Care. 41 (Suppl 1):S38–S50. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Bertakis KD, Azari R, Helms LJ, Callahan
EJ and Robbins JA: Gender differences in the utilization of health
care services. J Fam Pract. 49:147–452. 2000.PubMed/NCBI
|
|
37
|
Babu A, Mehta A, Guerrero P, Chen Z, Meyer
PM, Koh CK, Roberts R, Schaider J and Fogelfeld L: Safe and simple
emergency department discharge therapy for patients with type 2
diabetes mellitus and severe hyperglycemia. Endocr Pract.
15:696–704. 2009.PubMed/NCBI View Article : Google Scholar
|
